The U.S. Food and Drug Administration approved Mounjaro (tirzepatide) on August 28, 2026, to lower the risk of cardiovascular death, non-fatal heart attack, and non-fatal stroke in adults with type 2 diabetes who face elevated cardiovascular risk. Eli Lilly disclosed the decision the same day. The label expansion makes tirzepatide, a dual GIP and GLP-1 receptor agonist, the first drug in that mechanistic class to carry a cardiovascular risk-reduction indication in the United States.
Kenneth Custer, Ph.D., executive vice president and president of Lilly Cardiometabolic Health, called Mounjaro "the #1 most prescribed branded type 2 diabetes medicine for adults in the U.S." and said the approval gives those patients "a proven way to lower that risk, adding to the strong foundation it has already built in A1C and weight." The authorization permits physicians to prescribe the injectable specifically to reduce cardiovascular events rather than solely for glycemic control, a distinction that carries weight in formulary negotiations and prior-authorization reviews.
A Head-to-Head Trial, Not a Placeholder Study
Figure 1: Comparison of Mounjaro's cardiovascular non-inferiority to Trulicity versus the historical superiority of Ozempic over placebo.
The FDA grounded its decision in SURPASS-CVOT (NCT04255433), a randomized, double-blind Phase 3 trial that enrolled 13,299 adults with type 2 diabetes and established atherosclerotic cardiovascular disease across 30 countries. Median follow-up ran 210.1 weeks, roughly four and a half years. Lilly structured the study as the first cardiovascular-outcomes trial to pit two incretin medicines against each other rather than against placebo, the Daily Journal reported in its August 30 coverage.
On the primary MACE-3 composite endpoint, Mounjaro demonstrated non-inferiority to Trulicity (dulaglutide), Lilly's older GLP-1 agonist that received its own cardiovascular indication in 2020. Participants on Mounjaro experienced an 8 percent lower rate of cardiovascular death, heart attack, or stroke than those on Trulicity. Pharmaceutical Technology's analysis noted that superiority to dulaglutide was not formally established. Dr. Rachel Batterham, Lilly's senior vice president of medical innovation for cardiometabolic health, told Time the company chose Trulicity as the comparator precisely because it already carried proven cardiovascular benefit, setting what Custer described as "a higher bar."
That design choice means the 8 percent figure cannot be placed side-by-side with the roughly 20 percent MACE reduction Novo Nordisk demonstrated for Ozempic against placebo. Batterham acknowledged the limitation to Time: the trial answers whether Mounjaro performs at least as well as an existing cardiovascular-protective GLP-1 drug, not whether it outperforms semaglutide by a measurable margin. For prescribers weighing GLP-1, GIP, and multi-agonist options, the evidence base now rests on non-inferiority rather than direct superiority.
Matching Novo Nordisk on the Cardiovascular Label
Novo Nordisk secured a cardiovascular risk-reduction indication for Ozempic in 2020 and followed with a 2024 approval of Wegovy (semaglutide) for cardiovascular event reduction in non-diabetic adults with obesity and established heart disease. Lilly's Trulicity received a parallel indication in 2020. With Mounjaro's expansion, Lilly now markets two products carrying MACE-reduction labels, placing it on equal regulatory footing with Novo in the type 2 diabetes cardiovascular space. The Daily Journal's reporting noted the new indication is likely to make it easier for pharmacy benefit managers to approve coverage, though no specific formulary decisions have been announced.
The timing coincided with the European Society of Cardiology's annual congress opening in Munich the same Friday, a scheduling overlap that show the global commercial stakes. Fierce Pharma's reporting framed the approval as Lilly matching the 2020 Ozempic cardiovascular nod on a similar timeline, six years after Novo first moved. The European Medicines Agency has separately opened an assessment of Mounjaro for cardiovascular risk reduction in adults with type 2 diabetes and established disease, a parallel review whose outcome will determine whether the label expansion extends beyond U.S. prescribing.
What Remains Unresolved
The new indication applies to adults with type 2 diabetes at high cardiovascular risk. It does not cover heart failure, patients without diabetes, or the obesity indication marketed under the Zepbound brand name for the same tirzepatide molecule. Lilly is conducting a separate cardiovascular outcomes study of Zepbound in people without type 2 diabetes, Batterham told Time, but that trial has not reported results and no timeline for a potential cardiovascular label expansion in the obesity population appeared in the company's August 28 materials.
David D'Alessio, director of endocrinology and metabolism at Duke University School of Medicine and a SURPASS-CVOT co-author, said the approval gives patients "a medicine that reduces the risk of cardiovascular events and supports metabolic health at the same time." The FDA's full review documents for the supplemental application have not yet appeared in public listings. Lilly's next regulatory filing will likely address whether the agency requires post-marketing commitments tied to the non-inferiority design, a question the August 28 announcement left open.
Related Peptides Agora coverage examines weight loss peptides clinical mechanisms.
